INmune Bio submits EMA orphan drug application for Ebstrocel in RDEB - INMB News | RalliesINmune Bio submits EMA orphan drug application for Ebstrocel in RDEB
I
INMB• EMA filings for Ebstrocel in recessive dystrophic epidermolysis bullosa
- INmune Bio filed with the EMA for orphan drug designation for Ebstrocel in recessive dystrophic epidermolysis bullosa.
- A separate EMA scientific advice package was submitted to support a planned EU marketing authorization application in Q1 2027.
•
